e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages
Lydia Meziani, Michele Mondini, Benoît Petit, Alexandre Boissonnas, Vincent Thomas de Montpreville, Olaf Mercier, Marie-Catherine Vozenin, Eric Deutsch
Source:
Eur Respir J, 51 (3) 1702120; 10.1183/13993003.02120-2017
Journal Issue:
March
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lydia Meziani, Michele Mondini, Benoît Petit, Alexandre Boissonnas, Vincent Thomas de Montpreville, Olaf Mercier, Marie-Catherine Vozenin, Eric Deutsch. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J, 51 (3) 1702120; 10.1183/13993003.02120-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
LATE-BREAKING ABSTRACT: Overall survival after the introduction of CT-based follow-up after resection of lung cancer. A population based quality assurance analysis
No additional diagnostic gain of mediastinoscopy following sytematically and thouroughly performed mediastinal staging by EBUS-TBNA
How should PET influence the management of lung cancer?
Related content which might interest you:
Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 17: 180-189
Year: 2001
High expression of telomerase/endothelin-1 increase replication and activation of vascular myofibroblasts in usual interstitial pneumonia/idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
N-acetylcysteine reduces tumor necrosis factor-α release by alveolar macrophages of interstitial lung disease
in vitro
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2002; 20: Suppl. 38, 487s
Year: 2002
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 719s
Year: 2004
Bromodomain inhibitor JQ1 attenuates TGF-beta-suppressed
SOD2
expression and reduces proliferation in human primary pulmonary fibroblasts
Source: Annual Congress 2013 –The multiple faces of stress in lung injury
Year: 2013
M2 polarized alveolar macrophages in pulmonary fibrosis
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Attenuation of bleomycin-induced pulmonary fibrosis by direct thrombin inhibition is accompanied by a reduction in connective tissue growth factor mRNA levels
Source: Eur Respir J 2001; 18: Suppl. 33, 199s
Year: 2001
Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
Bleomycin induces cellular senescence in alveolar epithelial cells
Source: Eur Respir J 2003; 22: 436-443
Year: 2003
CCR7 deficiency induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009
Inhibition of acute lung inflammation by removal of pulmonary intravascular macrophages (PIMs)
Source: Eur Respir J 2001; 18: Suppl. 33, 79s
Year: 2001
The role of expression of TLR 4 in bleomycin-induced pulmonary fibrosis in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Treg depletion reduces bleomycin-induced pulmonary fibrosis by inducing Th17 and other CD4+T cell subset responses in lung
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept